When figures and data contradict text

MiR346 is apparently reduced in breast cancer tissue, contrary to claims by a paper's author

Debomoy Lahiri, Bryan Maloney, Kumar Sambamurti

Research output: Contribution to journalLetter

Abstract

A recent article in Gene highlighted potential function of miR-346 in human breast cancer (Yang et al., 2017). We request an explanation or correction of the report. In its current state, the text will certainly create confusion in the field and lead to incorrect assumptions. The authors made several critical errors. The abstract stated “we found that the expression of miR-346 was higher in breast cancer tissues than in their paired corresponding non-cancerous tissues” and the main text and legend for Fig. 1A stated “miR-346 expression was significantly higher in breast cancer tissues than in their paired corresponding non-cancerous tissues (Fig. 1A, Yang et al., 2017)” and “miR-346 was upregulated in breast cancer tissues and cell lines. (A)” respectively. It was also stated that “SRCIN1 expression levels were significantly down-regulated in breast cancer compared to the adjacent normal tissues (Fig. 5B, Yang et al., 2017)”. The problem with these statements is that they contradict the actual data presented in the paper! This misrepresentation of the effects of miR-346 in breast cancer could prove harmful by sidetracking future research. Further, clinical trials may be incorrectly directed towards lowering miR-346 without a complete and fair assessment of the internal contradictions in the data. Inaccurately-presented data impede progress of biomedical research, deplete scientific resources and compromise public trust.

Original languageEnglish (US)
Pages (from-to)46-47
Number of pages2
JournalGene
Volume635
DOIs
StatePublished - Nov 30 2017

Fingerprint

Breast Neoplasms
Biomedical Research
Clinical Trials
Cell Line
Genes

Keywords

  • Cancer
  • Gene regulation
  • microRNA
  • miR-346
  • Misleading results

ASJC Scopus subject areas

  • Genetics

Cite this

When figures and data contradict text : MiR346 is apparently reduced in breast cancer tissue, contrary to claims by a paper's author. / Lahiri, Debomoy; Maloney, Bryan; Sambamurti, Kumar.

In: Gene, Vol. 635, 30.11.2017, p. 46-47.

Research output: Contribution to journalLetter

@article{b86a4bdf325b45789ed8d806cb59c95d,
title = "When figures and data contradict text: MiR346 is apparently reduced in breast cancer tissue, contrary to claims by a paper's author",
abstract = "A recent article in Gene highlighted potential function of miR-346 in human breast cancer (Yang et al., 2017). We request an explanation or correction of the report. In its current state, the text will certainly create confusion in the field and lead to incorrect assumptions. The authors made several critical errors. The abstract stated “we found that the expression of miR-346 was higher in breast cancer tissues than in their paired corresponding non-cancerous tissues” and the main text and legend for Fig. 1A stated “miR-346 expression was significantly higher in breast cancer tissues than in their paired corresponding non-cancerous tissues (Fig. 1A, Yang et al., 2017)” and “miR-346 was upregulated in breast cancer tissues and cell lines. (A)” respectively. It was also stated that “SRCIN1 expression levels were significantly down-regulated in breast cancer compared to the adjacent normal tissues (Fig. 5B, Yang et al., 2017)”. The problem with these statements is that they contradict the actual data presented in the paper! This misrepresentation of the effects of miR-346 in breast cancer could prove harmful by sidetracking future research. Further, clinical trials may be incorrectly directed towards lowering miR-346 without a complete and fair assessment of the internal contradictions in the data. Inaccurately-presented data impede progress of biomedical research, deplete scientific resources and compromise public trust.",
keywords = "Cancer, Gene regulation, microRNA, miR-346, Misleading results",
author = "Debomoy Lahiri and Bryan Maloney and Kumar Sambamurti",
year = "2017",
month = "11",
day = "30",
doi = "10.1016/j.gene.2017.08.011",
language = "English (US)",
volume = "635",
pages = "46--47",
journal = "Gene",
issn = "0378-1119",
publisher = "Elsevier",

}

TY - JOUR

T1 - When figures and data contradict text

T2 - MiR346 is apparently reduced in breast cancer tissue, contrary to claims by a paper's author

AU - Lahiri, Debomoy

AU - Maloney, Bryan

AU - Sambamurti, Kumar

PY - 2017/11/30

Y1 - 2017/11/30

N2 - A recent article in Gene highlighted potential function of miR-346 in human breast cancer (Yang et al., 2017). We request an explanation or correction of the report. In its current state, the text will certainly create confusion in the field and lead to incorrect assumptions. The authors made several critical errors. The abstract stated “we found that the expression of miR-346 was higher in breast cancer tissues than in their paired corresponding non-cancerous tissues” and the main text and legend for Fig. 1A stated “miR-346 expression was significantly higher in breast cancer tissues than in their paired corresponding non-cancerous tissues (Fig. 1A, Yang et al., 2017)” and “miR-346 was upregulated in breast cancer tissues and cell lines. (A)” respectively. It was also stated that “SRCIN1 expression levels were significantly down-regulated in breast cancer compared to the adjacent normal tissues (Fig. 5B, Yang et al., 2017)”. The problem with these statements is that they contradict the actual data presented in the paper! This misrepresentation of the effects of miR-346 in breast cancer could prove harmful by sidetracking future research. Further, clinical trials may be incorrectly directed towards lowering miR-346 without a complete and fair assessment of the internal contradictions in the data. Inaccurately-presented data impede progress of biomedical research, deplete scientific resources and compromise public trust.

AB - A recent article in Gene highlighted potential function of miR-346 in human breast cancer (Yang et al., 2017). We request an explanation or correction of the report. In its current state, the text will certainly create confusion in the field and lead to incorrect assumptions. The authors made several critical errors. The abstract stated “we found that the expression of miR-346 was higher in breast cancer tissues than in their paired corresponding non-cancerous tissues” and the main text and legend for Fig. 1A stated “miR-346 expression was significantly higher in breast cancer tissues than in their paired corresponding non-cancerous tissues (Fig. 1A, Yang et al., 2017)” and “miR-346 was upregulated in breast cancer tissues and cell lines. (A)” respectively. It was also stated that “SRCIN1 expression levels were significantly down-regulated in breast cancer compared to the adjacent normal tissues (Fig. 5B, Yang et al., 2017)”. The problem with these statements is that they contradict the actual data presented in the paper! This misrepresentation of the effects of miR-346 in breast cancer could prove harmful by sidetracking future research. Further, clinical trials may be incorrectly directed towards lowering miR-346 without a complete and fair assessment of the internal contradictions in the data. Inaccurately-presented data impede progress of biomedical research, deplete scientific resources and compromise public trust.

KW - Cancer

KW - Gene regulation

KW - microRNA

KW - miR-346

KW - Misleading results

UR - http://www.scopus.com/inward/record.url?scp=85031111166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031111166&partnerID=8YFLogxK

U2 - 10.1016/j.gene.2017.08.011

DO - 10.1016/j.gene.2017.08.011

M3 - Letter

VL - 635

SP - 46

EP - 47

JO - Gene

JF - Gene

SN - 0378-1119

ER -